Site
Search results (6 results)
-
References | 21 Dec 2012
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
-
References | 27 Aug 2013
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;
Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, Gold RExpert Opin Pharmacother. 2013 Aug 24. PMID: 23971970. Abstract -
References | 6 Jul 2014
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).
Gold R, Giovannoni G, Phillips TJ, Fox RJ, Zhang A, Meltzer L, Kurukulasuriya NCMult Scler. 2014 Jul 2. PMID: 24990854. Abstract -
References | 8 Nov 2013
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Editors' PickHutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui M K, Taneja A, Deniz BCurr Med Res Opin. 2013 Nov 7. Epub 1969 Dec 31. PMID: 24195574. Abstract -
References | 12 Oct 2015
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience.
Gold R, Phillips TJ, Havrdova E, Bar-Or A, Kappos L, Kim N, Thullen T, Valencia P, Oliva L, Novas M, et al.Neurol Ther. 2015 Dec; 4(2):93-104. Epub 2015 Oct 12. PMID: 26662361. Abstract -
References | 22 May 2016
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, Macmanus DG, Yousry TA, Pozzilli C, Selmaj K, et al.Mult Scler. 2016 May 19. PMID: 27207449. Abstract